The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

J Hepatol. 2006 Apr;44(4):825; author reply 825-6. doi: 10.1016/j.jhep.2006.01.022. Epub 2006 Feb 9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy*
  • Hepatitis C, Chronic / genetics
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Polyethylene Glycols / therapeutic use*
  • RNA, Viral / analysis
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Time Factors
  • Viremia / complications*
  • Viremia / genetics

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a